Abstract
The performance of Oracol collection device (Oracol) for oral fluid sampling for SARS-CoV-2 molecular detection was compared to nasopharyngeal swabs (NPS). Samples (n = 128) were collected from symptomatic and asymptomatic adults after PCR confirmed COVID-19 on NPS. All samples were tested by 3 real-time PCR’s (RT-qPCR) for E, N and RdPR genes. Accuracy of Oracol compared to NPS was 38.28 % for E-gene, 47.66 % for RdRp-gene and 83.59 % for N-gene. A clear correlation between the N-gene Ct values on NPS and on Oracols was observed (p < 0.001). The sensitivity of the Oracol compared to the NPS increased in participants with an N-gene Ct value <30 on NPS (89.08%,) reaching 93.2 % with a N-gene Ct value <25. Oracol can be considered an alternative to NPS to detect SARS-CoV-2, especially in populations where NPS is not well tolerated.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Ghent University Hospital (Belgium) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
